抗血管生成药物对肿瘤免疫调节影响的研究进展

Research progress on the influence of anti-angiogenetic agents on antitumor immunity regulation

恶性肿瘤的治疗已进入"精准治疗"时代,抗肿瘤血管生成的靶向治疗是近年非常热门的研究方向,而肿瘤免疫逃逸是导致肿瘤治疗效果不理想的重要原因之一。抗血管生成治疗不仅能够抑制血管生成,使肿瘤退缩,并且能够减少肿瘤微环境中免疫抑制性细胞数量,提高肿瘤浸润淋巴细胞(tumor-infiltrating lymphocyte,TIL)、细胞毒性淋巴细胞(cytotoxic lymphocyte,CTL)等的数量,从而克服肿瘤免疫逃逸。本研究对抗血管生成药物通过改善肿瘤微环境,增强机体抗肿瘤免疫功能进行综述。

Malignant tumor therapy has entered a new era of ＂precise treatment.＂ Nowadays, targeted anti- angiogenic agents have become a popular research topic that continues to attract increasing interest. Tumor immune escape plays an indispensable role in therapeutic resistance. Anti-angiogenic therapies not only prevent the tumor angiogenesis and suppress tumor growth but also neutralize tumor escape from a host＇s immune system by reducing the immunosuppressive cells and increasing the number of tumor-infiltrating lymphocyte（TIL） and cytotoxic lymphocte（CTL）. This paper aims to review the mechanism underlying the manner by which anti-angiogenesis enhances immunity by influencing tumor microenvironment.